BofA reiterates Buy on IBM stock, keeps $300 price target By Investing.com

IBM’s setup is increasingly about multiple preservation versus multiple expansion. The software mix shift and cash generation support downside in the equity, but the market is likely to keep discounting any earnings quality that is driven by acquisition accounting or temporary cost discipline rather than durable organic acceleration. The most important second-order effect is that IBM’s capital allocation optionality improves if software valuations stay cheap: it can keep buying growth without needing heroic top-line inflection, which limits the probability of a near-term de-rating.

The weak spot is that guidance cadence matters more than the beat. A narrow increase in software outlook and softer margin trajectory suggest the business is still in “prove it” mode, so any disappointment in integration or cross-sell from the latest acquisition can hit sentiment quickly over the next 1-2 quarters. If pretax margin expansion does not re-accelerate by the next print, the stock may revert to being treated like a slow-growing software conglomerate rather than a quality compounder, especially if rates stay elevated and investors rotate toward cleaner secular growth.

The market may be underestimating how much of the upside is already embedded in the valuation through the dividend narrative. At these levels, IBM behaves like a bond proxy with modest upside unless software growth surprises sustainably above the low-teens and free cash flow converts into faster buybacks. On the other side, the article’s mention of acquisition optionality creates a hidden risk for CFLT: even if IBM is supportive of the asset class, deal speculation can compress standalone valuations in adjacent names if investors assume strategic buyers will remain active and price to takeout rather than fundamentals.